

Validation data for Bio-IC™

<https://www.invivogen.com/hpd1-bioassay>

For research use only

Version 21E04-NJ

PD-1/PD-L1 Bio-IC™ is a bioluminescent cell-based assay designed for the screening of novel inhibitors of the PD-1/PD-L1 immune checkpoint (IC) axis. The assay consists of two engineered cell lines. **Jurkat-Lucia™ TCR-hPD-1 effector cells** stably express a specific [HLA::peptide]-restricted TCR and an NFAT-inducible Lucia luciferase reporter gene. In addition, these cells overexpress human (h) CD28 stimulatory receptor (**Figure 1A**) and hPD-1 (programmed cell death 1) inhibitory receptor (**Figure 1B**). **Raji-APC-hPD-L1 cells** stably express the specific [HLA::peptide] and overexpress hPD-L1 (programmed cell death ligand 1) (**Figure 2**). These cells have been functionally tested with various Anti-hPD-1 or Anti-hPD-L1 hIgG1 mAbs. Upon addition of blocking mAbs, the PD-1/PD-L1 inhibitory interaction is disrupted and Jurkat-Lucia™ TCR-hPD-1 effector cells express Lucia luciferase in a dose-dependent manner (**Figure 3**).




Figure 1: Validation of human CD28 and PD-1 expression by Jurkat-Lucia™ TCR-hPD-1 cells. Jurkat-Lucia™ NFAT and Jurkat-Lucia™ TCR-hPD-1 cells were incubated with a PE-conjugated Anti-hCD28 (A) or APC-conjugated Anti-hPD-1 (B) mAb for 30 minutes. The binding affinity was then measured using flow cytometry.

PD-L1 expression on Raji-APC-derived cells




Figure 2: Validation of human PD-L1 expression by Raji-APC-hPD-L1 cells. Raji-APC-Null and Raji-APC-hPD-L1 cells were incubated with a PE-conjugated Anti-hPD-L1 mAb for 30 minutes. The binding affinity was then measured using flow cytometry.

Disruption of PD-1/PD-L1 inhibitory interaction using Anti-hPD-1 or Anti-hPD-L1 antibodies




Figure 3: Activation of Jurkat-Lucia™ TCR-hPD-1 cells. Raji-APC-hPD-L1 and Jurkat-Lucia™ TCR-hPD-1 cells were incubated with gradient concentrations of Anti-hPD-1 hIgG1 (Ni: Nivolumab variable region; Pem: Pembrolizumab variable region) or Anti-hPD-L1 mAbs for 6 hours. NFAT activation, reflecting the disruption of PD-1/PD-L1 inhibitory interaction, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. The fold increase over non induced cells (no mAbs) is shown.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873
InvivoGen USA (International): +1 (858) 457-5873
InvivoGen Europe: +33 (0) 5-62-71-69-39
InvivoGen Asia: +852 3622-3480
E-mail: info@invivogen.com



Any questions about our cell lines?
Visit our FAQ page.

 **InvivoGen**
www.invivogen.com